SEC 13F Intelligence

Data Collective IV GP, LLC / RXRX

Data Collective IV GP, LLC’s Recursion Pharmaceuticals In Position

Does Data Collective IV GP, LLC own Recursion Pharmaceuticals In (RXRX)? Yes — 5.94M shares worth $18M (+32.60% of its 13F portfolio) as of Q1 2026.

Position Value
$18M
Q1 2026
Shares
5.94M
% of Portfolio
+32.60%
Quarters Held
16
currently held

Position History RXRX

Reported value by quarter
Q4 ’21: $102MQ4 ’21Q3 ’22: $63MQ4 ’22: $46MQ4 ’22Q1 ’23: $40MQ2 ’23: $44MQ2 ’23Q3 ’23: $45MQ4 ’23: $59MQ4 ’23Q1 ’24: $59MQ2 ’24: $45MQ2 ’24Q3 ’24: $39MQ4 ’24: $40MQ4 ’24Q1 ’25: $31MQ2 ’25: $30MQ2 ’25Q3 ’25: $29MQ4 ’25: $24MQ4 ’25Q1 ’26: $18Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 20265.94M$18M+32.60%
Q4 20255.94M$24M+41.53%
Q3 20255.94M$29M+42.65%
Q2 20255.94M$30M+23.14%
Q1 20255.94M$31M+36.17%
Q4 20245.94M$40M+17.75%
Q3 20245.94M$39M+23.95%
Q2 20245.94M$45M+31.23%
Q1 20245.94M$59M+51.36%
Q4 20235.94M$59M+48.46%
Q3 20235.94M$45M+43.00%
Q2 20235.94M$44M+32.86%
Q1 20235.94M$40M+42.23%
Q4 20225.94M$46M+48.11%
Q3 20225.94M$63M+49.97%
Q4 20215.94M$102M+13.74%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Data Collective IV GP, LLC’s full portfolio or all institutional holders of RXRX.